We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
-9.4%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.21B
AUM Growth
-$432M
Cap. Flow
-$92.5M
Cap. Flow %
-4.18%
Top 10 Hldgs %
42.68%
Holding
227
New
13
Increased
52
Reduced
76
Closed
10

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$14.4M
2
CNC icon
Centene
CNC
+$8.41M
3
SNY icon
Sanofi
SNY
+$6.73M
4
LLY icon
Eli Lilly
LLY
+$6.66M
5
IQV icon
IQVIA
IQV
+$6.64M

Top Sells

Rank Stock Value
1
MRK icon
Merck
MRK
+$15.5M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$12.5M
3
JNJ icon
Johnson & Johnson
JNJ
+$11.1M
4
MDCO
Medicines Co
MDCO
+$10.3M
5
ELV icon
Elevance Health
ELV
+$9.94M

Sector Composition

Rank Sector Weight
1 Healthcare 95.66%
2 Real Estate 2.76%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BSX icon
26
Boston Scientific
BSX
$71.8B
$19.2M 0.87%
587,662
+23,317
+4% +$911K
ZTS icon
27
Zoetis
ZTS
$32.3B
$17.9M 0.81%
151,952
-38,432
-20% -$5.06M
BDX icon
28
Becton Dickinson
BDX
$46.7B
$17.9M 0.81%
79,698
+11,785
+17% +$2.91M
NBIX icon
29
Neurocrine Biosciences
NBIX
$16.9B
$17.8M 0.81%
206,150
+13,108
+7% +$1.28M
CNC icon
30
Centene
CNC
$31.3B
$17.1M 0.77%
288,194
+138,668
+93% +$8.41M
ISRG icon
31
Intuitive Surgical
ISRG
$134B
$16.9M 0.76%
102,117
-13,932
-12% -$2.55M
VTRS icon
32
Viatris
VTRS
$20.4B
$15.1M 0.68%
1,010,754
-27,800
-3% -$533K
ALNY icon
33
Alnylam Pharmaceuticals
ALNY
$29.3B
$15M 0.68%
137,617
-6,178
-4% -$713K
ELV icon
34
Elevance Health
ELV
$82.8B
$14.9M 0.67%
65,568
-36,464
-36% -$9.94M
NVS icon
35
Novartis
NVS
$292B
$14.8M 0.67%
179,847
-31,200
-15% -$2.78M
HUM icon
36
Humana
HUM
$44.4B
$14.5M 0.65%
46,130
-8,883
-16% -$3M
SNY icon
37
Sanofi
SNY
$103B
$14.3M 0.65%
327,367
+140,727
+75% +$6.73M
SRPT icon
38
Sarepta Therapeutics
SRPT
$1.66B
$13.7M 0.62%
140,129
-41,494
-23% -$4.74M
EW icon
39
Edwards Lifesciences
EW
$50.9B
$12.7M 0.57%
202,146
-6,525
-3% -$471K
AZN icon
40
AstraZeneca
AZN
$245B
$12.3M 0.56%
138,049
– –
PRAH
41
DELISTED
PRA Health Sciences, Inc.
PRAH
$11.9M 0.54%
143,508
-9,495
-6% -$926K
HZNP
42
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$11.8M 0.53%
399,257
+94,593
+31% +$3.2M
TECH icon
43
Bio-Techne
TECH
$11.2B
$10.9M 0.49%
230,764
+30,400
+15% +$1.52M
IDXX icon
44
Idexx Laboratories
IDXX
$44.8B
$9.77M 0.44%
40,314
-3,300
-8% -$861K
ACAD icon
45
Acadia Pharmaceuticals
ACAD
$4.38B
$9.36M 0.42%
221,599
+3,316
+2% +$137K
WELL icon
46
Welltower
WELL
$168B
$9.3M 0.42%
203,083
+11,437
+6% +$844K
ONC
47
BeOne Medicines Ltd
ONC
$32.4B
$9.23M 0.42%
74,984
-6,105
-8% -$955K
IONS icon
48
Ionis Pharmaceuticals
IONS
$9B
$9.13M 0.41%
193,201
-16,723
-8% -$932K
IQV icon
49
IQVIA
IQV
$38.5B
$8.87M 0.4%
82,266
+46,451
+130% +$6.64M
EXEL icon
50
Exelixis
EXEL
$13.7B
$8.87M 0.4%
515,125
– –
1
2
3 4 5

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2020 Portfolio in Review

As of Q1 2020, Tekla Capital Management held 227 positions worth $2.21B, down 16% from $2.64B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Tekla Capital Management withdrew a net $92.5M in Q1 2020, closing 10 positions and reducing 76 holdings. Its most notable exit was Medicines Co, an estimated $10.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Moderna worth $7.61M.

  • Tekla Capital Management's largest Q1 2020 buy was Moderna: 254,146 shares worth $7.61M.
  • Tekla Capital Management added most to Biogen in Q1 2020, an estimated $14.4M increase.
  • Tekla Capital Management's biggest Q1 2020 reduction was Merck, cutting an estimated $15.5M.
  • Tekla Capital Management fully exited Medicines Co in Q1 2020, selling an estimated $10.3M.
  • Tekla Capital Management's ten largest holdings make up 43% of its $2.21B portfolio in Q1 2020.
  • Tekla Capital Management opened 13 new positions and closed 10 in Q1 2020.
  • Tekla Capital Management's portfolio value fell 16% quarter-over-quarter to $2.21B.

Based on Tekla Capital Management's 13F filing for Q1 2020, filed 14 May 2020.